Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
vorsetuzumab mafodotin
(SGN-75) /
Pfizer
Welcome,
Profile
Billing
Logout
17 Diseases
0 Trials
0 Trials
6 News
||||||||||
vorsetuzumab mafodotin
(SGN-75) /
Seagen
P1 data, Trial termination, Combination therapy, Metastases:
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
(clinicaltrials.gov) - Jan 23, 2014
P1
, N=4, Terminated,
Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Terminated
||||||||||
vorsetuzumab mafodotin
(SGN-75) /
Seagen
P1 data, Enrollment change, Combination therapy, Metastases:
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
(clinicaltrials.gov) - Jan 23, 2014
P1
, N=4, Terminated,
Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Terminated N=40 --> 4
||||||||||
vorsetuzumab mafodotin
(SGN-75) /
Seagen
New P1 trial, P1 data, Combination therapy, Metastases:
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
(clinicaltrials.gov) - Aug 30, 2012
P1
, N=4, Terminated,
Sponsor: Seattle Genetics, Inc.
|||
|||||||
vorsetuzumab mafodotin
(SGN-75) /
Seagen
Trial completion, Metastases:
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
(clinicaltrials.gov) - Jul 19, 2012
P1
, N=58, Completed,
Sponsor: Seattle Genetics, Inc.
N=40 --> 4 Active, not recruiting --> Completed
||
||||||||
vorsetuzumab mafodotin
(SGN-75) /
Seagen
Enrollment change, Metastases:
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
(clinicaltrials.gov) - Apr 1, 2012
P1
, N=58, Completed,
Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Completed N=113 --> 58